Navigation Links
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/3/2009

SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Thomas Weisel Partners Healthcare Conference on Thursday, September 10, 2009 at 3:15 p.m. EDT (12:15 p.m. PDT). The conference is being held at the Four Seasons Hotel in Boston. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.

Dr. Worland will also present at the Rodman & Renshaw Annual Global Investment Conference on Friday, September 11, 2009 at 11:15 a.m. EDT (8:15 a.m. PDT). The conference is being held at the New York Palace Hotel in New York City.

Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software. A replay of the presentations will be available approximately one hour after the live webcasts conclude and will be available through September 25, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended June 30, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
2. Anadys Pharmaceuticals to Present at the Citi Biotech Day
3. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. Anadys Pharmaceuticals to Present at Bio Investor Forum
8. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
9. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
10. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
11. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and athletic trainers ... say researchers presenting their work at the American Orthopaedic Society for Sports ... evaluating the patterns of change in concussion symptom presentation, diagnostic tools used and ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... IT operations analytics and application performance monitoring (APM) solutions, has expanded its ... services providers. , According to Peter Ohrenberger, sales director at Nastel, “We’ve ...
(Date:7/20/2017)... ... 20, 2017 , ... For individuals with extended hospital stays or who are ... such facilities are specially designed to accommodate patients with a wide range of ailments ... from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially designed armrest ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... Team Type ... access to medicine for everyone affected by diabetes, is teaming up with a Microsoft ... global event kicks off on July 24th. , “Team Type 1’s mission overlaps ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology: